Volume 17, Number 12—December 2011
Research
Candidate Cell Substrates, Vaccine Production, and Transmissible Spongiform Encephalopathies
Table 1
Variable | sCJD | vCJD | BSE | 22L-scrapie |
---|---|---|---|---|
Actual or candidate cell lines for vaccine production | ||||
CHO-K1 | Y | Y | Y | |
Vero C1008 | Y | Y | Y | |
WI-38 | Y | Y | Y | |
MDCK | Y | Y | Y | |
HEK-293 | Y | Y | Y | |
Other cells resistant to TSE infection | ||||
MBDK | Y | |||
EBTR | Y | |||
BT | Y | |||
BCE C/D-1b | Y | |||
BL3.1 | Y | |||
R9ab | Y | Y | Y | |
Cells infectable with 22L scrapie | ||||
Mo3F4-3T3 | Y | |||
L929 | Y |
*sCJD, sporadic Creutzfeldt-Jakob disease; vCJD, variant Creutzfeldt-Jakob disease; BSE, bovine spongiform encephalopathy; CHO-KI, Chinese hamster ovary; Vero C1008, African green monkey kidney; WI-38, human lung diploid fibroblasts; MDCK, dog kidney; HEK-293, human embryonic kidney; MBDK, bovine kidney; EBTR, bovine trachea; BT, bovine turbinate; BCE C/D-1b, bovine cornea; BL3.1, bovine B lymphocytes; R9ab, rabbit fibroblasts; Mo3F4-3T3, mouse embryo fibroblasts; L929, mouse embryo fibroblasts; Y, experiment was completed.
Page created: November 30, 2011
Page updated: November 30, 2011
Page reviewed: November 30, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.